{"product_id":"ilmn-bcg-matrix","title":"(ILMN) Illumina, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Illumina, Inc. BCG Matrix helps you see how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework, making it useful for strategy, portfolio review, and investment analysis. The page already shows a real preview of the actual report content, so you can review what you’re buying before you purchase. Get the full version to access the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovaSeq X Plus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovaSeq X Plus is Illumina, Inc.'s flagship high-throughput sequencer and the main growth engine in large research and population-scale genomics. It can deliver up to 20,000 whole genomes a year and cuts sequencing cost to about $200 per genome, pushing older NovaSeq 6000 systems out. Its 25B and 100B flow cells make it the clear \"Star\" asset in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMiSeq i100 Series\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMiSeq i100 Series is a Star for Illumina, Inc. in the lower-throughput, benchtop sequencing niche, since it fits smaller labs that need decentralized testing and faster turnaround. The refresh helps defend share against niche competitors and keeps Illumina relevant in routine, local workflows. This matters because the platform targets a segment where speed and ease of use drive repeat purchases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDRAGEN Bio-IT Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDRAGEN Bio-IT Platform is a Star because it powers secondary analysis for alignment and variant calling, and it is built into research and clinical sequencing workflows. Its use rises with sequencing volume, so software revenue can scale faster than hardware while keeping gross margins high. In Illumina, Inc.’s FY2025 and FY2026 pipeline, that makes DRAGEN a sticky, recurring-value engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNextSeq 2000\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNextSeq 2000 is a mid-throughput system for translational and applied research, built for labs that need speed, flexibility, and solid sample scaling. Its run formats fit multi-sample workflows, so it stays useful as testing volume rises. That keeps it in the \"Star\" zone because demand is still strong and the platform is still relevant.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMid-throughput, flexible workflow fit\u003c\/li\u003e\n\u003cli\u003eStrong use in translational research\u003c\/li\u003e\n\u003cli\u003eUseful for growing multi-sample labs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNovaSeq 6000Dx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovaSeq 6000Dx is a regulated clinical sequencing platform that helps diagnostic labs move into FDA-cleared workflows. It sits in a growing clinical market, where Illumina reported $4.3 billion in FY2024 revenue and clinical adoption keeps widening as labs scale higher-throughput testing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA-cleared clinical workflow\u003c\/li\u003e\n\u003cli\u003eBuilt for diagnostic labs\u003c\/li\u003e\n\u003cli\u003eAdoption still expanding\u003c\/li\u003e\n\u003cli\u003eBest fit: Star\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIllumina’s Star Products: Growth Drivers in Sequencing and Software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIllumina, Inc. Stars are the platforms with the clearest growth: NovaSeq X Plus, MiSeq i100 Series, DRAGEN Bio-IT Platform, and NextSeq 2000. They sit in high-demand research and clinical niches, with NovaSeq X Plus driving scale and DRAGEN adding recurring software revenue. NovaSeq 6000Dx also supports expanding regulated clinical use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStar signal\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovaSeq X Plus\u003c\/td\u003e\n\u003ctd\u003eHighest growth\u003c\/td\u003e\n\u003ctd\u003eUp to 20,000 genomes\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDRAGEN\u003c\/td\u003e\n\u003ctd\u003eRecurring\u003c\/td\u003e\n\u003ctd\u003eScales with sequencing volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eIllumina’s BCG Matrix maps its sequencing businesses by growth and share to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG Matrix snapshot for Illumina, Inc. to pinpoint cash cows, stars, and weak spots fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for Illumina’s key claims, boosting credibility and speeding investor due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSequencing consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIllumina, Inc.'s sequencing consumables are the Cash Cows: reagents, flow cells, and cartridges are repeat buys tied to the installed base, so revenue keeps coming even when new instrument sales slow. In FY2025, this recurring model still supported a multibillion-dollar product franchise and remained the core of the company's cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfinium microarrays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInfinium microarrays remain a cash cow for Illumina, Inc. because genotyping and array demand in research and applied genomics is mature, standardized, and repeatable. With a large installed base and routine reorder patterns, they keep generating stable cash with limited extra spend. That steady base helps offset slower growth areas in the business.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService and maintenance contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eService and maintenance contracts are a cash cow for Illumina, Inc.: instrument support, calibration, and repair agreements generate steady, low-growth cash from the installed base. In FY2024, Illumina reported $4.33 billion in revenue, and recurring service tied to placements helps smooth demand swings. These contracts protect uptime and keep labs locked into the platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSample prep and library kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSample prep and library kits are classic Cash Cows for Illumina, Inc.: they are upstream consumables bought before each sequencing run, so orders repeat with installed-base usage, not new-market growth. In fiscal 2025, this type of consumable revenue stayed high-margin and tied to recurring customer activity, making it a steadier profit source than instrument sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat buys from existing labs\u003c\/li\u003e\n\u003cli\u003eHigh gross-margin consumables mix\u003c\/li\u003e\n\u003cli\u003eDemand follows run volume\u003c\/li\u003e\n\u003cli\u003eLow need for new customer creation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensing and collaboration revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLicensing and collaboration revenue is a Cash Cow for Illumina, Inc.: it monetizes core IP through technology access and development deals, so it brings in cash without heavy factory spend. The stream is low-growth, but it is margin-friendly and steadier than instrument sales; in FY2025, Illumina still used it to support a business with about $3B in total revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonetizes IP, not hardware\u003c\/li\u003e\n\u003cli\u003eLow growth, steady cash\u003c\/li\u003e\n\u003cli\u003eNeeds little manufacturing capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIllumina’s recurring revenue keeps cash flowing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIllumina, Inc.'s cash cows are recurring consumables, service, and IP-linked revenue. These lines are tied to the installed base, so they keep cash flowing even as instrument demand softens. In FY2025, they still anchored a business with about $3B in revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003eRepeat run-based buys\u003c\/td\u003e\n\u003ctd\u003eCore recurring revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService\u003c\/td\u003e\n\u003ctd\u003eInstalled-base support\u003c\/td\u003e\n\u003ctd\u003eFY2024 revenue: $4.33B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eLow-capex IP cash\u003c\/td\u003e\n\u003ctd\u003eSteady, margin-friendly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eIllumina, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Illumina, Inc. BCG Matrix report you’ll receive after purchase. The full document is delivered in the same professional format, with no watermarks or demo content. What you see here is what you’ll download—ready to use for analysis, presentations, or strategy work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMiniSeq\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMiniSeq is an older low-throughput sequencer with a max output of about 7.5 Gb per run, so it sits in a shrinking niche as labs move to newer systems. Replacement risk is high because Illumina’s newer platforms deliver far more scale and better economics. For BCG, MiniSeq fits Dogs: low growth, limited share, and weak long-term demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiSeq 100\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eiSeq 100 fits the Dog box in Illumina, Inc.'s BCG Matrix: it is an entry-level desktop sequencer with limited scale and a low share in a slow-growth market. It serves small labs that need a simple, lower-cost system, but it does not drive enough volume or profit to be a core growth engine. Illumina does not give a 2025 unit split for iSeq 100, so its weak strategic weight is judged from its niche role, not a disclosed sales figure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHiSeq 2500 and 4000\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHiSeq 2500 and 4000 are legacy high-output systems that Illumina has largely replaced with NovaSeq platforms, so their growth is now minimal. In 2025, the installed base still supports some reagent and service revenue, but the economics keep fading as customers migrate to newer systems. That makes them classic Dogs: low-growth assets with shrinking strategic value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOlder microarray workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder microarray workflows sit in a shrinking niche for legacy applied-genomics tests, while sequencing keeps taking share because it offers higher throughput and broader variant coverage. Illumina, Inc. still sees array demand in some low-cost, targeted use cases, but the segment has weak expansion potential and limited strategic lift versus sequencing-based tools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy use only\u003c\/li\u003e\n\u003cli\u003eWeak sequencing share\u003c\/li\u003e\n\u003cli\u003eLow growth runway\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStandalone custom genotyping services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStandalone custom genotyping services fit Dogs: they serve narrow, bespoke customer needs, so volumes stay small and margins get squeezed by commoditization. For Illumina, Inc., this is a low-scale niche with little strategic lift versus core sequencing platforms, so it should not drive meaningful growth or pricing power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall, custom, low-volume work\u003c\/li\u003e\n\u003cli\u003eHard to scale profitably\u003c\/li\u003e\n\u003cli\u003eEasy to commoditize\u003c\/li\u003e\n\u003cli\u003eWeak strategic advantage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIllumina’s Legacy Lines: Low-Growth Dogs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMiniSeq, iSeq 100, HiSeq 2500\/4000, and legacy microarray and custom genotyping lines are Dogs in Illumina, Inc.'s BCG Matrix: low growth, limited share, and weak strategic pull as customers shift to higher-throughput systems. MiniSeq tops out near 7.5 Gb per run, and Illumina’s NovaSeq platforms have already reset buyer expectations. These niches can still earn some 2025 service and reagent revenue, but the runway is short.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMiniSeq\u003c\/td\u003e\n\u003ctd\u003eLow growth\u003c\/td\u003e\n\u003ctd\u003e~7.5 Gb\/run\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eiSeq 100\u003c\/td\u003e\n\u003ctd\u003eNiche share\u003c\/td\u003e\n\u003ctd\u003eEntry-level desktop\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHiSeq 2500\/4000\u003c\/td\u003e\n\u003ctd\u003eLegacy\u003c\/td\u003e\n\u003ctd\u003eReplaced by NovaSeq\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovaSeqDx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovaSeqDx sits in Illumina, Inc.’s Question Mark bucket: it targets regulated clinical sequencing, a growing space as labs move toward FDA-cleared workflows. The upside is real, but share is still small versus entrenched diagnostic incumbents, so adoption costs and proof points matter. If Illumina turns the platform into a repeatable clinical standard, it can shift from bet to Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTruSight Oncology 500 v2\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTruSight Oncology 500 v2 fits the Question Mark bucket: it targets a fast-growing tumor-profiling market, but scale is still limited versus entrenched competitors. Broad genomic profiling is gaining ground in hospitals and reference labs, helped by demand for a 500-gene panel plus RNA fusion and MSI reporting. The growth case is real, but adoption still needs more installed base, workflow wins, and reimbursement depth to turn share into scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReproductive health sequencing workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReproductive health sequencing workflows stay a Question Mark for Illumina, Inc. because prenatal, carrier screening, and PGT use cases are still expanding as genomic testing moves into routine care. The market is growing, but lab uptake depends on clear clinical utility and payer reimbursement, which can slow conversion.\u003c\/p\u003e\n\u003cp\u003eIllumina’s win rate should improve if more labs adopt sequencing-based workflows, but today the category is still early and uneven across regions. In 2025, reimbursement changes and higher test volume matter more than raw demand, since that decides whether this becomes a scale business or stays niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAgricultural genomics sequencing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIllumina, Inc. should treat agricultural genomics sequencing as a Question Mark: the plant and animal genomics market is growing, but it is fragmented and tied to many specific use cases, so scale is uneven. In 2025, the global agricultural genomics market was estimated in the mid-single-digit billions of dollars, while Illumina’s core human health sequencing stayed far larger, so share here remains modest.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eGrowth is real, but use cases are narrow.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePlant and animal work needs many assays.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eFragmentation limits easy share gains.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eCore human health still drives scale.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpatial and multiomics partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpatial and multiomics partnerships fit the Question Mark box: demand is rising in pharma and academic labs, but Illumina still relies mostly on collaborators for new workflows, so direct market control remains limited. The upside is real, but the capture rate is still low.\u003c\/p\u003e\n\u003cp\u003eThese programs can expand reach into spatial transcriptomics, proteomics, and other multiomics use cases without heavy standalone build-out, which matters as the biology toolkit gets broader in 2025-2026. Still, partnership-led access means Illumina owns less of the workflow than in core sequencing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth biology workflows\u003c\/li\u003e\n\u003cli\u003eDemand rising in pharma and academia\u003c\/li\u003e\n\u003cli\u003ePartnerships limit pricing power\u003c\/li\u003e\n\u003cli\u003eNeeds more direct platform control\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIllumina’s High-Potential Bets Are Still Early-Stage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIllumina, Inc.’s Question Marks are still early-stage bets: NovaSeqDx, TruSight Oncology 500 v2, reproductive health, agriculture, and multiomics can grow fast, but 2025 share is still modest and reimbursement, workflow proof, and partner control are the bottlenecks.\u003c\/p\u003e\n\u003cp\u003eNovaSeqDx and oncology panels have the clearest upside, while reproductive and agricultural genomics stay fragmented; Illumina’s 2025-2026 focus is turning pilot use into repeatable clinical volume.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eQuestion Mark\u003c\/th\u003e\n\u003cth\u003eKey 2025-2026 data\u003c\/th\u003e\n\u003cth\u003eWhy it is still a bet\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovaSeqDx\u003c\/td\u003e\n\u003ctd\u003eFDA-cleared clinical sequencing\u003c\/td\u003e\n\u003ctd\u003eLow share, high adoption cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTruSight Oncology 500 v2\u003c\/td\u003e\n\u003ctd\u003e500-gene panel + RNA\/MSI\u003c\/td\u003e\n\u003ctd\u003eNeeds more installed base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReproductive health\u003c\/td\u003e\n\u003ctd\u003eCarrier, prenatal, PGT\u003c\/td\u003e\n\u003ctd\u003eReimbursement still uneven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234520768777,"sku":"ilmn-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ilmn-bcg-matrix.webp?v=1785721758","url":"https:\/\/dcfanalyst.com\/products\/ilmn-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}